Every 8-K that BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BCTXL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTXL filings page.
BriaCell Therapeutics furnished unaudited interim financial statements and MD&A for its subsidiary BriaPro Therapeutics for the three and nine months ended April 30, 2026. BriaPro reported a net loss of $240,005 for the quarter and $712,236 for the nine-month period, driven mainly by pre-clinical research and development spending of $649,991.
As of April 30, 2026, BriaPro had total assets of $1,321,744, cash of $299,950, current liabilities of $2,239,636 and a working capital deficit of $1,937,495, with an accumulated deficit of $1,892,661. The statements emphasize material uncertainty about BriaPro’s ability to continue as a going concern and its dependence on BriaCell for funding.
During the period, BriaPro acquired BriaCell’s exclusive sCD80 cancer immunotherapy license and related assets by issuing 23,972,589 common shares valued at $846,532, increasing BriaCell’s ownership to about 78%. BriaCell also provided a credit facility of up to $3,000,000, of which $300,000 has been advanced to support sCD80 development.
BriaCell Therapeutics Corp. entered a Placement Agency Agreement with ThinkEquity for a best efforts equity offering of 1,449,300 common shares at $3.25 per share. The offering generated gross proceeds of about $4.71 million before fees and expenses.
The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives. The shares were issued under an effective shelf registration statement on Form S-3. As compensation, BriaCell paid a cash fee of 7.5% of gross proceeds and issued Placement Agent Warrants to buy 72,465 common shares at an exercise price of $4.0625 per share, exercisable immediately and expiring five years after the agreement date.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.